Claims for Patent: 12,268,745

Summary for Patent: 12,268,745

Title:	Material and method for treating internal cavities
Abstract:	A hydrophilic biocompatible sustained-release material is disclosed. The material comprises amounts of an ethylene oxide/propylene oxide block copolymer, HPMC, and water, effective to produce a composition of sufficiently low viscosity at room temperature to be injectable into an internal body cavity via a tube inserted within a urinary catheter. At body temperature, the material exhibits a much higher viscosity and will stably adhere to the internal surface of a body cavity. As the material dissolves, a therapeutic agent incorporated therein is slowly released to the body cavity, while the material itself is excreted from the body.
Inventor(s):	Asher Holzer, Dorit Daniel, Michael MULLERAD, Jaime De La Zerda, Uri SHPOLANSKY, Nadav MALCHI, Yosh DOLLBERG, Dor TAL, Yossi YAVIN
Assignee:	Urogen Pharma Ltd
Application Number:	US18/625,862
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 12,268,745
Patent Claims:	1. A method of treating renal pelvis cancer comprising: (a) preparing a composition by incorporating an effective amount of mitomycin C and an accompanying excipient into a thermoreversible hydrogel, the accompanying excipient being mannitol; and (b) administering the composition to a renal pelvis of a human in need of such treatment, wherein the thermoreversible hydrogel comprises: (i) 23% to 27% (w/w) poloxamer 407; (ii) 0.15% to 0.2% (w/w) hydroxypropylmethylcellulose; (iii) 0.5% to 1.8% (w/w) PEG-400; and (iv) water. 2. The method of claim 1, wherein the composition is administered via a urinary catheter. 3. The method of claim 2, wherein the thermoreversible hydrogel comprises 27% (w/w) poloxamer 407. 4. The method of claim 2, wherein the thermoreversible hydrogel comprises 0.2% (w/w) hydroxypropylmethylcellulose. 5. The method of claim 2, wherein the thermoreversible hydrogel comprises 0.5% to 1.0% (w/w) PEG-400. 6. The method of claim 3, wherein the thermoreversible hydrogel comprises 0.2% (w/w) hydroxypropylmethylcellulose. 7. The method of claim 6, wherein the thermoreversible hydrogel comprises 0.5% to 1.0% (w/w) PEG-400. 8. The method of claim 7, wherein the thermoreversible hydrogel comprises 1.0% (w/w) PEG-400.